Semaglutide Pre-Mixed Research Pen - 5mg

SEMAGLUTIDE is a synthetic agonist of the GLP-1 receptor, a key incretin hormone that regulates glucose metabolism and appetite. Developed for use in research in metabolic and weight regulation studies. Mimics the action of the natural incretin hormone GLP-1, improving insulin secretion and reducing appetite in research models.

SEMAGLUTIDE is a long-acting GLP-1 receptor agonist studied for its ability to improve glycemic control, promote weight loss, and increase metabolic efficiency. Mimics endogenous glucagon-1-like peptide to stimulate insulin secretion, suppress glucagon release, and delay gastric emptying, providing sustained metabolic regulation.

In clinical research, SEMAGLUTIDE has been shown to significantly reduce body weight and improve lipid profile by suppressing appetite, increasing energy expenditure, and improving insulin sensitivity. These effects make it one of the most studied peptides in obesity and metabolic health research.

SEMAGLUTIDE also contributes to cardiometabolic protection by improving endothelial function, reducing inflammation, and lowering blood pressure and triglycerides. Its neuroendocrine effects extend to appetite-regulating centres in the hypothalamus, contributing to long-term behavioural changes in caloric intake and energy balance.

Formulated in a stabilized premixed injection pen for subcutaneous administration, Semаglutе ensures high systemic bioavailability and precise dosage control under experimental conditions. It is an essential research peptide for studies focused on obesity, diabetes, and energy metabolism. Formulated in a stabilized pre-mixed injection pen. Intended exclusively for laboratory and research use. 

• Benefits:

§  Potent GLP-1 Receptor Agonist for Metabolic Regulation:
SEMAGLUTIDE is a synthetic GLP-1 receptor agonist widely studied for its ability to increase insulin secretion, suppress glucagon release, and delay gastric emptying. These combined actions improve glycemic control and promote energy balance, making it one of the most effective peptides under investigation for obesity and type 2 diabetes.

§  Significant weight reduction in long-term studies:
Human clinical trials show that SEMAGLUTIDE produces average weight reductions of between 12% and 16% through appetite suppression, improved insulin sensitivity, and improved fat metabolism. This effect of sustained fat loss positions semaglutide as a leading peptide in experimental models of weight control and body recomposition.

§  Improved glycemic control and insulin sensitivity:
SEMAGLUTIDE improves glucose-dependent insulin secretion and pancreatic beta cell function. It reduces HbA1c and fasting glucose levels without causing hypoglycemia, providing a balanced metabolic profile, ideal for studies focused on glucose tolerance, insulin resistance, and diabetic metabolism.

§  Visceral Fat Reduction and Lipid Optimization:
Clinical and preclinical research demonstrates that SEMAGLUTIDE reduces visceral and hepatic fat accumulation by modulating lipid oxidation and suppressing hepatic lipogenesis. These effects contribute to improved liver enzyme levels, lipid profiles, and overall cardiovascular health, making it valuable in metabolic and liver research applications.

§  Regulation of appetite and caloric intake:
Through its action on the hypothalamic centers of satiety, SEMAGLUTIDE reduces appetite and cravings, while prolonging the feeling of postprandial satiety. This appetite-regulating mechanism promotes sustained caloric reduction and forms the basis of its efficacy in weight control and obesity research models.

§  Cardiometabolic protection and vascular health:
Studies reveal that SEMAGLUTIDE lowers LDL cholesterol, triglycerides, and systolic blood pressure, while improving endothelial function. These effects provide strong evidence of its cardioprotective potential, making it a promising candidate in research on the synergy between cardiovascular and metabolic health.

§  Reduction of inflammatory and oxidative stress markers:
Administration of semaglutide has been associated with decreased levels of CRP, TNF-α, and IL-6, reflecting a reduction in systemic inflammation. It also improves oxidative balance by increasing antioxidant defenses, which contributes to cell protection in models of metabolic stress.

§  Preservation of lean muscle mass during fat loss: 
Unlike extreme calorie restriction or pharmacological methods for weight loss, Semаglutе selectively reduces adipose tissue, preserving lean muscle mass. This supports long-term metabolic stability and is consistent with research focusing on body recomposition and muscle retention during fat reduction.

§  Improved liver health and NAFLD parameters:
In models of non-alcoholic fatty liver disease (NAFLD), semaglutide has been shown to reduce hepatic steatosis, inflammation, and fibrosis. These results are related to an improvement in lipid metabolism, mitochondrial function and insulin signaling, highlighting their potential in liver and metabolic disorder research.

§  Improved mitochondrial function and energy efficiency:
Semaglutide improves mitochondrial biogenesis and respiratory efficiency in adipose and muscle tissue. By increasing energy expenditure and cellular respiration, it supports studies focused on energy optimization, endurance, and longevity in metabolic research.

§  Synergistic potential with other metabolic peptides:
Research often explores the combination of SEMAGLUTIDE with cagrilintide, AOD-9604, or TIRZEPATIDE to improve fat oxidation, appetite control, and glucose homeostasis. These synergistic interactions extend their application in advanced models of metabolic and body composition research.

§  Long-term metabolic adaptation and weight maintenance:
Long-term follow-up studies show that those taking semglutide maintain most of their weight loss even after stopping it, indicating long-lasting metabolic reprogramming. This sustained adaptation supports their research in long-term studies on energy regulation, obesity relapse prevention, and recovery of metabolic health.

Pre-Mixed Cartridge and Kit:

• 1 x Cartridge
• 1 x Peptide Cartridge Pen
• 1 x Pen Carry Case
• 8 x Pen Needle Tips

Single Mixed Cartridges (1,2 & 3) Come with:

• 1,2 or 3 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
• 8 x Pen Needle Tips

The single 1,2 & 3 cartridges do not come with a kit.

Handling and Storage:

• Store this product in a dry place, away from sunlight and moisture
• Keep each unit sealed when not in use
• Store at 2-8 °C to minimise freeze thaw, prepare aliquots according to your protocol
• 4 x Use only within research protocols that follow your lab’s SOPs and local regulations

For Research Use Only

This product is supplied strictly for scientific research and laboratory experimentation. It is not intended for human consumption, clinical use or any form of therapeutic application.